Innate Pharma S.A. ADR (IPHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -53,533 | -8,193 | -61,217 | -62,478 | -73,089 |
| Depreciation Amortization | 2,158 | 5,510 | 47,839 | 5,438 | 64,879 |
| Accounts receivable | 56,065 | -14,791 | -4,429 | N/A | N/A |
| Accounts payable and accrued liabilities | -1,094 | -4,213 | -8,073 | N/A | N/A |
| Other Working Capital | 42,907 | -34,732 | -13,172 | -11,694 | -56,208 |
| Other Operating Activity | -53,965 | 21,182 | 18,872 | -426 | 5,284 |
| Operating Cash Flow | $-7,462 | $-35,238 | $-20,181 | $-69,161 | $-59,134 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 10,377 | N/A | N/A | N/A | N/A |
| PPE Investments | -423 | -218 | -564 | -1,091 | -1,026 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -3,427 |
| Sale Of Investment | N/A | 24,642 | 3,161 | N/A | N/A |
| Purchase Sale Intangibles | N/A | -2,165 | -619 | -474 | -11,851 |
| Other Investing Activity | 1 | -2,095 | -620 | 6 | -10,820 |
| Investing Cash Flow | $9,955 | $22,329 | $1,978 | $-1,085 | $-15,273 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 33,955 | 1,554 |
| Debt Repayment | -9,670 | -2,555 | -2,135 | -2,448 | -2,565 |
| Common Stock Issued | 3,168 | 428 | 209 | 590 | 55 |
| Other Financing Activity | 0 | 0 | 0 | -369 | -388 |
| Financing Cash Flow | $-6,501 | $-2,128 | $-1,926 | $31,728 | $-1,345 |
| Exchange Rate Effect | -547 | 297 | -451 | -571 | 250 |
| Beginning Cash Position | 76,402 | 91,157 | 109,317 | 161,839 | 231,758 |
| End Cash Position | 71,847 | 76,416 | 88,740 | 122,754 | 156,258 |
| Net Cash Flow | $-4,555 | $-14,741 | $-20,578 | $-39,086 | $-75,502 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,462 | -35,238 | -20,181 | -69,161 | -59,134 |
| Capital Expenditure | -423 | -380 | -564 | -1,099 | -1,036 |
| Free Cash Flow | -7,885 | -35,617 | -20,744 | -70,260 | -60,170 |